Leah Croll, MD, Assistant Professor of Clinical Neurology at the Lewis Katz School of Medicine at Temple University, offered expert commentary to Healthline about newly released results from a Phase 3 clinical trial of the experimental Alzheimer’s drug, donanemab. Eli Lilly announced this week that the trial showed that the drug appears to be effective in helping slow cognitive decline in people with Alzheimer’s disease.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH